Want to see AU:ALC full AI Analyst Report?
Top Page
Alcidion Group Limited
(Sydney:ALC)
Select Model
Select Model
Rating:65Neutral
Price Target:
AU$0.12
â–²(18.00% Upside)
Action:Reiterated
Date:10/28/26
The score is primarily supported by improving financial performance—especially an exceptionally low-debt balance sheet and positive recent cash generation—while the main drag is valuation, with a very high P/E. Technical signals are modestly constructive (price above key moving averages) but momentum indicators remain largely neutral, limiting upside confidence.
Positive Factors
Very low leverage
Extremely low leverage gives Alcidion substantial financial flexibility and minimizes refinancing and interest burdens. This conservative capital structure can support continued investment in healthcare software, help absorb operating volatility, and reduce balance-sheet pressure as the business pursues growth.
Negative Factors
Modest profitability
Despite the return to profitability, Alcidion is retaining only a modest share of revenue as profit. Thin margins leave less room to absorb cost increases or execution setbacks and may limit the pace at which the company can reinvest in products, sales, and platform development.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Extremely low leverage gives Alcidion substantial financial flexibility and minimizes refinancing and interest burdens. This conservative capital structure can support continued investment in healthcare software, help absorb operating volatility, and reduce balance-sheet pressure as the business pursues growth.
Read all positive factors
Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$148.48M
Dividend YieldN/A
Average Volume (3M)672.97K
Price to Earnings (P/E)64.7
Beta (1Y)0.88
Revenue Growth26.61%
EPS Growth41.67%
CountryAU
Employees141
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,349,805,200
10 Day Avg. Volume611,067
30 Day Avg. Volume672,966
Financial Highlights & Ratios
PEG Ratio1.48
Price to Book (P/B)1.55
Price to Sales (P/S)2.73
P/FCF Ratio21.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside47.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$53.65M
Alcidion Group Limited Business Overview & Revenue Model
Company Description
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platfor...
Alcidion Group Limited Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
88
Very Positive
Cash Flow
70
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.64M | 40.79M | 37.06M | 40.40M | 34.35M |
| Gross Profit | 9.16M | 35.99M | 31.92M | 1.25M | 3.29M |
| EBITDA | 2.55M | 4.03M | -4.50M | -1.43M | -1.58M |
| Net Income | 2.29M | 1.65M | -8.42M | -3.62M | -4.41M |
Balance Sheet | |||||
| Total Assets | 121.88M | 115.63M | 114.46M | 120.68M | 128.35M |
| Cash, Cash Equivalents and Short-Term Investments | 20.64M | 17.70M | 11.80M | 14.64M | 17.34M |
| Total Debt | 814.00K | 1.41M | 1.70M | 2.15M | 2.48M |
| Total Liabilities | 31.01M | 27.82M | 27.52M | 30.52M | 34.40M |
| Stockholders Equity | 90.87M | 87.80M | 86.94M | 90.17M | 93.95M |
Cash Flow | |||||
| Free Cash Flow | 6.62M | 5.64M | -7.18M | -285.00K | 685.00K |
| Operating Cash Flow | 6.85M | 5.76M | -7.13M | 169.00K | 996.00K |
| Investing Cash Flow | -1.70M | -125.00K | -53.00K | -3.14M | -59.74M |
| Financing Cash Flow | -800.00K | -764.00K | 4.34M | -616.00K | 51.33M |
Alcidion Group Limited Technical Analysis
Positive
0.10
Price Trends
0.10
Positive
0.10
Positive
0.10
Positive
Market Momentum
<0.01
Negative
79.92
Negative
84.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 79.92 is Negative, neither overbought nor oversold. The STOCH value of 84.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.
Alcidion Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$20.73B | 78.41 | 63.19% | 0.35% | 22.87% | 130.30% | |
65 Neutral | AU$148.48M | 64.71 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$109.10M | -6.93 | -203.69% | ― | -1.53% | 28.29% | |
47 Neutral | AU$61.10M | -6.84 | -24.29% | ― | -17.35% | -47.29% | |
45 Neutral | AU$22.74M | -1.22 | -58.13% | ― | 2.08% | -195.31% | |
44 Neutral | AU$425.45M | -15.23 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:ALC
Alcidion Group Limited
0.11
<0.01
10.00%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.13
-0.06
-31.58%
AU:PME
Pro Medicus Limited
198.41
-69.59
-25.97%
AU:M7T
Mach7 Technologies
0.26
-0.02
-8.77%
AU:BMT
Beamtree Holdings Ltd
0.08
-0.12
-61.50%
AU:AYA
Artrya Limited
2.60
-0.69
-20.97%
Alcidion Group Limited Corporate Events
Alcidion Sets Timetable for Consolidation of Shares and Performance Rights
Oct 8, 2026
Alcidion Group Limited has announced a security consolidation affecting its ordinary fully paid shares and performance rights, subject to security holder approval obtained on 12 November 2026. Trading in the post‑consolidation securities is ...
Alcidion to Execute 1-for-10 Share Consolidation to Simplify Capital Structure
Oct 8, 2026
Alcidion Group Limited plans to consolidate its share capital on a 1-for-10 basis, reducing its ordinary shares from about 1.35 billion to roughly 135 million and performance rights from 26.7 million to about 2.7 million, subject to shareholder ap...
Alcidion calls virtual 2026 AGM as it advances digital health strategy
Oct 8, 2026
Alcidion Group Limited has convened its 2026 Annual General Meeting, which will be held virtually on 12 November 2026 at 4:00pm AEDT, and has released the accompanying Notice of Meeting, proxy form and access letter. The board’s decision to ...
Alcidion Director William Smart Acquires 200,000 Shares in On-Market Trades
Oct 7, 2026
Alcidion Group Limited has disclosed a change in director William Smart’s interests in company securities, indicating his indirect acquisition of 200,000 fully paid ordinary shares via Citicorp Nominees Pty Limited as custodian. The on-marke...
Alcidion Seeks ASX Quotation for 6.2 Million New Shares
Sep 3, 2026
Alcidion Group Limited has applied for quotation on the ASX of 6,246,397 new fully paid ordinary shares, to be issued on 4 September 2026. The additional securities arise from the exercise or conversion of existing options or other convertible ins...
ASX drops quarterly cash flow reporting for financially strengthened Alcidion
Sep 3, 2026
Healthcare technology provider Alcidion Group Limited has secured relief from the Australian Securities Exchange’s requirement to lodge quarterly cash flow reports, reflecting a significantly strengthened balance sheet and operating performa...
Alcidion Director Andrew Way Increases Shareholding via On-Market Trade
Aug 27, 2026
Alcidion Group Limited has reported a change in the shareholding of director Andrew Way, in line with ASX disclosure rules and the Corporations Act. The company remains focused on compliance with market regulations that govern director interests a...
Alcidion Director Andrew Way Boosts Shareholding in On-Market Trades
Aug 27, 2026
Alcidion Group Limited has disclosed a change in director Andrew Way’s holdings, with the director purchasing additional fully paid ordinary shares in two on-market trades. The acquisitions, executed at $0.093 per share, increased Way’...
Alcidion Details 2026 Governance and Diversity Framework
Aug 18, 2026
Alcidion Group Limited has released its 2026 Corporate Governance Statement, outlining how its Board oversees strategy, risk and management while aiming to protect shareholder interests and consider broader stakeholders. The statement details the ...
Alcidion Files ASX Corporate Governance Statement for 2026
Aug 18, 2026
Alcidion Group Limited has lodged its annual corporate governance disclosures with the ASX for the year ended 30 June 2026, including an Appendix 4G and a governance statement made available through its website. The governance statement, approved ...
Alcidion Releases FY26 Results Presentation with Extensive Investor Disclaimers
Aug 18, 2026
Alcidion Group Limited has released its FY26 results presentation, outlining financial and operational information for the period in Australian dollars and highlighting the use of non‑IFRS metrics such as underlying NPAT and EBITDA. The docu...
Alcidion posts record FY26 profit as Kyra acquisition and NHS deals fuel growth
Aug 18, 2026
Alcidion reported FY26 revenue of $51.6 million, up 27% year on year, with 63% generated in the U.K. and 37% in ANZ, and lifted Annual Recurring Revenue to $38.3 million, a 34% increase. Underlying EBITDA rose 34% to $6.8 million and NPAT climbed ...
Alcidion to Present FY26 Results in Investor Webcast
Aug 12, 2026
Alcidion Group Limited, a healthcare IT specialist focused on clinical decision support and interoperability, has built its offering around the Miya Precision platform to help hospitals and healthcare organisations improve patient outcomes. The co...
Alcidion Issues 1.9 Million Unquoted Performance Rights Under Incentive Scheme
Aug 11, 2026
Alcidion Group Limited has notified the market of the issue of 1,912,175 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 12 August 2026, reflecting...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.